Scancell plc is delighted to announce that Prof. Lindy Durrant, Joint CEO of the Company, will be presenting a paper entitled “Phase I/II trial of a novel antibody DNA immunotherapy, SCIB1 ImmunoBody which targets CD64, in the treatment of Melanoma” at SMi’s 3rd Annual Cancer Vaccine conference, 15-16 September 2014, in London. The paper will describe interim results, as at December 2013, from the Company’s ongoing Phase I/II trial. Of the 25 patients recruited at that time, 23 were treated with SCIB1 per protocol. Of these, 20 patients were considered to have shown an immune response

For further detail on the conference see: http://www.smi-online.co.uk/pharmaceuticals/uk/conference/cancer-vaccines